Journal Article

DZNE-2020-05174

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Amyloid-β 1-24 C-terminal truncated fragment promotes amyloid-β 1-42 aggregate formation in the healthy brain.

Mazzitelli, S. (First author)DZNE* ; Filipello, F. ; Rasile, M. ; Lauranzano, E. ; Starvaggi-Cucuzza, C. ; Tamborini, M. ; Pozzi, D. ; Barajon, I. ; Giorgino, T. ; Natalello, A. ; Matteoli, M. (Corresponding author)

2016
Biomed Central London

This record in other databases:    

Please use a persistent id in citations: doi:10.1186/s40478-016-0381-9

Abstract: Substantial data indicate that amyloid-β (Aβ), the major component of senile plaques, plays a central role in Alzheimer's Disease and indeed the assembly of naturally occurring amyloid peptides into cytotoxic aggregates is linked to the disease pathogenesis. Although Aβ42 is a highly aggregating form of Aβ, the co-occurrence of shorter Aβ peptides might affect the aggregation potential of the Aβ pool. In this study we aimed to assess whether the structural behavior of human Aβ42 peptide inside the brain is influenced by the concomitant presence of N-terminal fragments produced by the proteolytic activity of glial cells. We show that the occurrence of the human C-terminal truncated 1-24 Aβ fragment impairs Aβ42 clearance through blood brain barrier and promotes the formation of Aβ42 aggregates even in the healthy brain. By showing that Aβ1-24 has seeding properties for aggregate formation in intracranially injected wild type mice, our study provide the proof-of-concept that peptides produced upon Aβ42 cleavage by activated glial cells may cause phenotypic defects even in the absence of genetic mutations associated with Alzheimer's Disease, possibly contributing to the development of the sporadic form of the pathology.

Keyword(s): Alzheimer Disease: metabolism (MeSH) ; Alzheimer Disease: pathology (MeSH) ; Amyloid beta-Peptides: administration & dosage (MeSH) ; Amyloid beta-Peptides: metabolism (MeSH) ; Animals (MeSH) ; Brain: metabolism (MeSH) ; Brain: pathology (MeSH) ; Disease Models, Animal (MeSH) ; Humans (MeSH) ; Learning Disabilities: metabolism (MeSH) ; Learning Disabilities: pathology (MeSH) ; Matrix Metalloproteinase 9: genetics (MeSH) ; Matrix Metalloproteinase 9: metabolism (MeSH) ; Memory Disorders: metabolism (MeSH) ; Memory Disorders: pathology (MeSH) ; Mice (MeSH) ; Mice, Inbred BALB C (MeSH) ; Mice, Inbred C57BL (MeSH) ; Mice, Knockout (MeSH) ; Mice, Transgenic (MeSH) ; Microglia: metabolism (MeSH) ; Microglia: pathology (MeSH) ; Motor Activity: physiology (MeSH) ; Peptide Fragments: administration & dosage (MeSH) ; Peptide Fragments: metabolism (MeSH) ; Plaque, Amyloid: metabolism (MeSH) ; Plaque, Amyloid: pathology (MeSH) ; Protein Folding (MeSH) ; Protein Multimerization (MeSH) ; Social Behavior (MeSH) ; Amyloid beta-Peptides ; Peptide Fragments ; amyloid beta-peptide (1-24) ; amyloid beta-protein (1-42) ; Matrix Metalloproteinase 9 ; Mmp9 protein, mouse

---

Contributing Institute(s):

1. Genome Biology of Neurodegenerative Diseases (AG Heutink)

Research Program(s):

1. 345 - Population Studies and Genetics (POF3-345) (POF3-345)

Appears in the scientific report 2016

---

Database coverage:
; ; ; ; Clarivate Analytics Master Journal List ; DOAJ Seal ; Ebsco Academic Search ; IF >= 5 ; JCR ; NCBI Molecular Biology Database ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---